Geovax Labs (Geovax Labs) Short Percentage of Float

View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Geovax Labs's Short Percentage of Float

For the Biotechnology subindustry, Geovax Labs's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Geovax Labs's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Geovax Labs's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Geovax Labs's Short Percentage of Float falls into.

Geovax Labs (Geovax Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVXW) » Definitions » Short Percentage of Float

Comparable Companies

Traded in Other Exchanges

GOVX:USA E8L:Germany

Address

1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080

Website

https://www.geovax.com

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.